Thursday February 25th | 3:00 pm (Paris) - 9:00 am (New York)
Today strong evidence is available indicating that screening with high-risk HPV assays is more effective in preventing future cervical precancer and cancer than cytology-based screening. Therefore, more and more countries are moving from microscopic inspection of cytological lesions towards detection of nucleic acids of HPV as main screening methodology. However, it is crucial that only well validated assays are applied in screening programs. This EUROGIN webinar will update the list of high-risk HPV assays that fulfil the international validation criteria anno 2020.